Related Experiment Video

Updated: May 15, 2025

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

2.5K

Diabetes and calcific aortic valve disease: implications of glucose-lowering medication as potential therapy

Feng Liu1, Haipeng Cai1

  • 1Department of Cardiology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.

Frontiers in Pharmacology
|May 13, 2025
PubMed

Insights

Calcific aortic valve disease (CAVD) is a serious condition with no current drug treatments. This review explores glucose-lowering medications as potential therapies to slow CAVD progression, particularly in diabetic patients.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Calcific aortic valve disease (CAVD) is a progressive condition with high mortality for symptomatic patients.
  • Currently, no pharmacotherapies exist to prevent CAVD progression, necessitating valve replacement.
  • The rising prevalence of diabetes in CAVD patients complicates management due to shared risk factors and molecular pathways.

Purpose of the Study:

  • To review the current knowledge on glucose-lowering medications for their potential to retard the progression of CAVD.
  • To assess the efficacy of various glucose-lowering agents in managing CAVD, considering their impact on atherosclerotic cardiovascular disease.

Main Methods:

  • Literature review of studies assessing glucose-lowering medications in the context of CAVD.
  • Analysis of molecular links between diabetes and CAVD, including inflammation, oxidative stress, and endothelial dysfunction.
  • Evaluation of clinical trial data for traditional cardiovascular drugs and glucose-lowering agents in CAVD.

Main Results:

  • Traditional cardiovascular drugs have shown limited success in slowing CAVD progression.
  • Several glucose-lowering medications have demonstrated potential in decelerating CAVD development.
  • Molecular links such as inflammation, oxidative stress, and endothelial dysfunction connect diabetes and CAVD.

Conclusions:

  • Glucose-lowering medications represent promising therapeutic options for retarding CAVD progression.
  • Further research is warranted to establish the role of specific glucose-lowering agents in CAVD management.
  • Addressing diabetes and its comorbidities is crucial for managing complex CAVD cases.

Keywords:
calcific aortic valve diseasediabetesdipeptidyl peptidase-4 inhibitorsglucose-lowering medicationperoxisome proliferator-activated receptor γ agonists

More Related Videos

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

3.9K
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.4K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
126
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
714
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
394